Omar Nadeem MD
Hematologic Oncology
Multiple Myeloma Physician Dana-Farber Cancer Institute
Join to View Full Profile
450 Brookline AveBoston, MA 02115
Dr. Nadeem is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Rhode Island Hospital/Brown University HealthFellowship, Hematology and Medical Oncology, 2012 - 2015
Dartmouth-Hitchcock/Mary Hitchcock Memorial HospitalResidency, Internal Medicine, 2009 - 2012
Ross University School of MedicineClass of 2009
Certifications & Licensure
FL State Medical License 2024 - Present
RI State Medical License 2012 - 2026
VT State Medical License 2024 - 2026
CT State Medical License 2022 - 2025
MA State Medical License 2015 - 2025
ME State Medical License 2022 - 2025
Clinical Trials
- DARA RVD For High Risk SMM Start of enrollment: 2021 Mar 08
- A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma Start of enrollment: 2022 Oct 27
Roles: Principal Investigator
Publications & Presentations
PubMed
- Real-World Experience with Teclistamab for Relapsed/ Refractory Multiple Myeloma from the U.S. Myeloma Immunotherapy Consortium.Beatrice M Razzo, Shonali Midha, Andrew J Portuguese, Ariel F Grajales-Cruz, Andre De Menezes Silva Corraes
Blood Cancer Discovery. 2025-07-09 - Invasive fungal disease is rare in patients with relapsed/refractory multiple myeloma treated with BCMA CAR T-cell therapy.Jessica S Little, Angelica Medina Pena, E Bridget Kim, Andrew J Yee, Omar Nadeem
Blood Advances. 2025-06-25 - Prospective study of immunogenicity to SARS-CoV-2 booster vaccines in multiple myeloma and Waldenström macroglobulinemia.Andrew R Branagan, Clifton C Mo, Matthew M Lei, Joshua Gustine, Andrew J Yee
Blood Advances. 2025-06-05
Abstracts/Posters
- A Phase II Study of Elotuzumab in Combination with Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple MyelomaOmar Nadeem, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Defining the Differentiation States of Multiple Myeloma at Single Cell Resolution Reveals Opportunities for ImmunotherapyOmar Nadeem, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple MyelomaOmar Nadeem, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Press Mentions
When Is Treating a Precursor Condition Harmful?October 8th, 2024- Study Shows That Immune System Holds Clues to Patients with High-Risk Smoldering Myeloma Likely to Benefit from TreatmentNovember 15th, 2022
Immunotherapeutic and Targeted Approaches in Multiple MyelomaOctober 14th, 2020- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
